Data / Drug companies / Deflazacort
Deflazacort: 11 companies and 55 products in the FDA NDC directory
Deflazacort is listed in the FDA National Drug Code Directory by 11 companies, with 55 products in commercial distribution. 50 of the products (90.9%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are tablet; suspension, and the newest product started marketing on October 7, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 11
- Products
- 55
- Generic (ANDA) products
- 50 (90.9%)
- Application numbers
- 11
- Routes
- Oral
- Brand names
- Jaythari, Kymbee, Emflaza, Jaythari Oral Suspension, Pyquvi
- openFDA record search
- api.fda.gov
Companies that list deflazacort
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Doppel Farmaceutici S.r.l. | 10 | tablet; suspension | Generic drugs (ANDA) | November 20, 2025 |
| Zydus Pharmaceuticals USA Inc. | 10 | tablet; suspension | Generic drugs (ANDA) | November 20, 2025 |
| PTC Therapeutics, Inc. | 5 | tablet; suspension | New drug applications (NDA) | September 10, 2018 |
| Upsher-Smith Laboratories, LLC | 5 | tablet; suspension | Generic drugs (ANDA) | June 5, 2026 |
| Amneal Pharmaceuticals NY LLC | 4 | tablet | Generic drugs (ANDA) | December 12, 2025 |
| Aurobindo Pharma Limited | 4 | tablet | Generic drugs (ANDA) | February 9, 2024 |
| AvKARE | 4 | tablet | Generic drugs (ANDA) | December 10, 2025 |
| Hikma Pharmaceuticals USA Inc. | 4 | tablet | Generic drugs (ANDA) | October 7, 2026 |
| Sun Pharmaceutical Industries, Inc. | 4 | tablet | Generic drugs (ANDA) | March 19, 2025 |
| Upsher-Smith Laboratories, LLC | 4 | tablet | Generic drugs (ANDA) | November 5, 2024 |
| Aucta Pharmaceuticals, Inc. | 1 | suspension | Generic drugs (ANDA) | June 30, 2025 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 48 | 87.3% |
| Suspension | 7 | 12.7% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 50 | 90.9% |
| New drug applications (NDA) | 5 | 9.1% |
Pharmacologic classes
| Class | Products |
|---|---|
| Corticosteroid | 55 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.